Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2023 May 15

PMID 37186073

Authors

Ching-Yee Loo

Wing-Hin Lee

Qi Tony Zhou

Affiliations

Soon will be listed here.

Abstract

With the rapid outbreak of respiratory viral infections, various biological (e.g. vaccines, peptides, recombinant proteins, antibodies and genes) and antiviral agents (e.g. ribavirin, palivizumab and valaciclovir) have been successfully developed for the treatment of respiratory virus infections such as influenza, respiratory syncytial virus and SARS-CoV-2 infections. These therapeutics are conventionally delivered via oral, intramuscular or injection route and are associated with several adverse events due to systemic toxicity. The inherent in vivo instability of biological therapeutics may hinder them from being administered without proper formulations. Therefore, we have witnessed a boom in nanotechnology coupled with a needle-free administration approach such as the inhalation route for the delivery of complex therapeutics to treat respiratory infections. This review discussed the recent advances in the inhalation strategies of nanoformulations that target virus respiratory infections.

Citing Articles

Advances and Challenges in Antiviral Development for Respiratory Viruses.

De Jesus-Gonzalez L, Leon-Juarez M, Lira-Hernandez F, Rivas-Santiago B, Velazquez-Cervantes M, Mendez-Delgado I Pathogens. 2025; 14(1).

PMID: 39860981 PMC: 11768830. DOI: 10.3390/pathogens14010020.

Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review.

Rai C, Kuo T, Chen Y Vaccines (Basel). 2024; 12(9).

PMID: 39340032 PMC: 11436249. DOI: 10.3390/vaccines12091002.

Fc-empowered exosomes with superior epithelial layer transmission and lung distribution ability for pulmonary vaccination.

Meng F, Xing H, Li J, Liu Y, Tang L, Chen Z Bioact Mater. 2024; 42:573-586.

PMID: 39308551 PMC: 11416621. DOI: 10.1016/j.bioactmat.2024.08.015.

Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine.

Cojocaru E, Petris O, Cojocaru C Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204164 PMC: 11357421. DOI: 10.3390/ph17081059.

Aerosol Inhalation of Gene Delivery Therapy for Pulmonary Diseases.

Huang Y, Zhang J, Wang X, Jing H, Li H Biomolecules. 2024; 14(8).

PMID: 39199292 PMC: 11352762. DOI: 10.3390/biom14080904.

References

Jin X, Ren J, Li R, Gao Y, Zhang H, Li J . Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021; 37:100986. PMC: 8343248. DOI: 10.1016/j.eclinm.2021.100986. View

Assane D, Makhtar C, Abdoulaye D, Amary F, Djibril B, Niokhor D . Viral and Bacterial Etiologies of Acute Respiratory Infections Among Children Under 5 Years in Senegal. Microbiol Insights. 2018; 11:1178636118758651. PMC: 5815418. DOI: 10.1177/1178636118758651. View

Ftouh M, Kalboussi N, Abid N, Sfar S, Mignet N, Bahloul B . Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses. PPAR Res. 2021; 2021:6741290. PMC: 8550859. DOI: 10.1155/2021/6741290. View

Baldassi D, Ambike S, Feuerherd M, Cheng C, Peeler D, Feldmann D . Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes. J Control Release. 2022; 345:661-674. PMC: 8963978. DOI: 10.1016/j.jconrel.2022.03.051. View

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Groneberg D, Witt C, Wagner U, Chung K, Fischer A . Fundamentals of pulmonary drug delivery. Respir Med. 2003; 97(4):382-7. DOI: 10.1053/rmed.2002.1457. View

Loo C, Lee W . Nanotechnology-based therapeutics for targeting inflammatory lung diseases. Nanomedicine (Lond). 2022; 17(12):865-879. DOI: 10.2217/nnm-2021-0447. View

Ari A . Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med. 2020; 167:105987. PMC: 7172670. DOI: 10.1016/j.rmed.2020.105987. View

10.

Chauhan G, Madou M, Kalra S, Chopra V, Ghosh D, Martinez-Chapa S . Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano. 2020; 14(7):7760-7782. DOI: 10.1021/acsnano.0c04006. View

11.

Varnai B, Malanga M, Sohajda T, Beni S . Molecular interactions in remdesivir-cyclodextrin systems. J Pharm Biomed Anal. 2021; 209:114482. PMC: 8609759. DOI: 10.1016/j.jpba.2021.114482. View

12.

Degoey D, Grampovnik D, Flosi W, Marsh K, Wang X, Klein L . Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir. J Med Chem. 2009; 52(9):2964-70. DOI: 10.1021/jm900080g. View

13.

Goodarzi N, Barazesh Morgani A, Abrahamsson B, Cristofoletti R, Groot D, Langguth P . Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. J Pharm Sci. 2016; 105(4):1362-9. PMC: 7126353. DOI: 10.1016/j.xphs.2016.01.017. View

14.

Letko M, Marzi A, Munster V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4):562-569. PMC: 7095430. DOI: 10.1038/s41564-020-0688-y. View

15.

Jackson C, Farzan M, Chen B, Choe H . Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2021; 23(1):3-20. PMC: 8491763. DOI: 10.1038/s41580-021-00418-x. View

16.

Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H . Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021; 21(12):1654-1664. PMC: 8313090. DOI: 10.1016/S1473-3099(21)00396-0. View

17.

Li J, Wu S, Guo X, Tang R, Huang B, Chen X . Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022; 10(8):739-748. PMC: 9122540. DOI: 10.1016/S2213-2600(22)00087-X. View

18.

Esparza T, Chen Y, Martin N, Bielefeldt-Ohmann H, Bowen R, Tolbert W . Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19. MAbs. 2022; 14(1):2047144. PMC: 8928829. DOI: 10.1080/19420862.2022.2047144. View

19.

Huo J, Mikolajek H, Le Bas A, Clark J, Sharma P, Kipar A . A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Commun. 2021; 12(1):5469. PMC: 8458290. DOI: 10.1038/s41467-021-25480-z. View

20.

Li C, Zhan W, Yang Z, Tu C, Hu G, Zhang X . Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 2022; 185(8):1389-1401.e18. PMC: 8907017. DOI: 10.1016/j.cell.2022.03.009. View